Skip to content

TRIZLEX BIOPHARMA OÜ

Registry code (registrikood) 11220756Private limited company (Osaühing)VAT EE101030128Activity (EMTAK 70201): Äri- ja muu juhtimisalane nõustamineActive

Saue vald, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€1.3M
▲ 30.5% vs 2024
Profit before tax (2025)
€900k
Employees, FTE (2025)
2
State taxes paid, last 4 quarters
€150k

Revenue, profit and employees, 2019–2025

€193k2019€245k2020€521k2021€285k2022€744k2023€987k2024€1.3M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€192,893€50,541€50,541€69,2531
2020€245,004€50,604€50,604€119,8571
2021€520,626-€16,087-€16,087€103,7702
2022€285,240€40,720€40,720€144,4902
2023€744,425€323,849€323,849€470,8952
2024€987,018€418,807€418,807€892,2582
2025€1,288,202€824,080€900,245€1,373,6962

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€11,511€75,153€5,900—€69,253
2020€112,157€182,399€2,542€60,000€119,857
2021€44,540€135,770€0€32,000€103,770
2022€68,395€238,990€0€94,500€144,490
2023€38,551€606,395€0€135,500€470,895
2024€711,638€948,958€20,000€36,700€892,258
2025€36,358€1,423,742€13,346€36,700€1,373,696

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€8,952€772€59,0332
2022 Q2€7,621€812€87,4612
2022 Q3€3,100€812€60,9462
2022 Q4€4,540€812€60,7002
2023 Q1€13,881€1,289€215,3332
2023 Q2€15,327€1,528€130,9172
2023 Q3€13,784€1,528€173,9362
2023 Q4€21,518€1,528€198,8152
2024 Q1€25,954€2,805€170,8952
2024 Q2€25,913€4,613€431,4312
2024 Q3€4,450€4,613€234,4492
2024 Q4€17,539€4,613€380,8062
2025 Q1€5,544€4,906€356,3212
2025 Q2€17,803€5,069€282,9412
2025 Q3€12,740€5,101€330,7822
2025 Q4€25,628€5,101€261,9562
2026 Q1€42,227€5,476€463,4352
2026 Q2€28,844€5,664€521,4342
2026 Q3€53,068€5,488€676,8952

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), TRIZLEX BIOPHARMA OÜ reported revenue of €1,288,202.

The company closed the 2025 financial year with a net profit of €900,245.

Revenue increased by 30.5% from €987,018 in 2024 to €1,288,202 in 2025.

Revenue grew at a compound annual rate of 37.2% between 2019 and 2025.

Equity accounted for 96.5% of total assets of €1,423,742 at the end of the 2025 reporting period.

With 2 full-time-equivalent employees in 2025, revenue per employee was €644,101.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, TRIZLEX BIOPHARMA OÜ reported €1,923,720 in turnover.

EMTA recorded 2 employees for the quarter ending Q3 2026, compared with 2 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.